Sonoma Pharmaceuticals (SNOA) has shared an update.
During the adjourned annual meeting on August 23, 2024, Sonoma Pharmaceuticals, Inc.’s stockholders made several key decisions including the election of two Class I directors, approval of executive compensation, and rejection of the company’s reincorporation from Delaware to Nevada. Additionally, they approved an increase in authorized shares, the 2024 Equity Incentive Plan, a reverse stock split, and the appointment of a new independent accounting firm. These decisions will significantly shape the company’s governance and financial strategy moving forward. A press release regarding the reverse stock split was subsequently issued.
See more insights into SNOA stock on TipRanks’ Stock Analysis page.
